HALOZYME THERAPEUTICS, INC. Acquisitions, Net of Cash Acquired
HALOZYME THERAPEUTICS, INC. (HALO) reported Acquisitions, Net of Cash Acquired of $725.97 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-17.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired · last filed 2026-02-17
- HALOZYME THERAPEUTICS, INC. payments to acquire businesses, net of cash acquired for the quarter ending 2023-12-31 was $0.00.
- HALOZYME THERAPEUTICS, INC. payments to acquire businesses, net of cash acquired for the quarter ending 2023-09-30 was $0.00.
- HALOZYME THERAPEUTICS, INC. payments to acquire businesses, net of cash acquired for the quarter ending 2022-12-31 was $0.00.
- HALOZYME THERAPEUTICS, INC. payments to acquire businesses, net of cash acquired for the quarter ending 2022-09-30 was $0.00.
- HALOZYME THERAPEUTICS, INC. payments to acquire businesses, net of cash acquired for fiscal 2025 was $725.97M.
- HALOZYME THERAPEUTICS, INC. payments to acquire businesses, net of cash acquired for fiscal 2024 was $0.00.
- HALOZYME THERAPEUTICS, INC. payments to acquire businesses, net of cash acquired for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- HALOZYME THERAPEUTICS, INC. payments to acquire businesses, net of cash acquired for fiscal 2022 was $999.12M.
| Period end | Payments to Acquire Businesses, Net of Cash Acquired 3 month | Payments to Acquire Businesses, Net of Cash Acquired 6 month | Payments to Acquire Businesses, Net of Cash Acquired 9 month | Payments to Acquire Businesses, Net of Cash Acquired 12 month |
|---|---|---|---|---|
| 2025-12-31 | $725.97M 10-K · filed 2026-02-17 | |||
| 2024-12-31 | $0.00 10-K · filed 2026-02-17 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $0.00 derived: sum of 2 quarters · filed 2026-02-17 | $0.00 10-K · filed 2026-02-17 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $0.00 10-Q · filed 2023-11-06 | ||
| 2023-06-30 | $0.00 10-Q · filed 2023-08-08 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $0.00 derived: sum of 2 quarters · filed 2025-02-18 | $999.12M 10-K · filed 2025-02-18 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $999.12M 10-Q · filed 2023-11-06 | ||
| 2022-06-30 | $999.12M 10-Q · filed 2023-08-08 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $0.00 derived: sum of 2 quarters · filed 2024-02-20 | $0.00 10-K · filed 2024-02-20 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $0.00 10-Q · filed 2022-11-08 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-09 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |